New combo therapy aims to boost immune fight against pancreatic cancer
NCT ID NCT05846516
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This study tests a new immunotherapy for adults with advanced pancreatic cancer. The treatment uses a special protein and virus to help the immune system kill cancer cells, combined with another drug called ezabenlimab. The goal is to find a safe dose and see if the combination can help people live longer without the cancer growing. About 58 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asklepios Kliniken Hamburg GmbH
Hamburg, 22763, Germany
-
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, 1011, Switzerland
-
Clara Campal Comprehesive Cancer Center
Madrid, 28050, Spain
-
Hopitaux Universitaires de Geneve (HUG)
Geneva, CH-1205, Switzerland
-
Hospital General Universitario Gregorio Marañón
Madrid, 28007, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Hospital Universitario Reina Sofía
Córdoba, 14004, Spain
-
Institut Curie Saint-Cloud
Saint-Cloud, 92210, France
-
Institut Gustave Roussy
Villejuif, 94800, France
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Orlando Health Cancer Institute
Orlando, Florida, 32806, United States
-
Perlmutter Cancer Center at NYU Langone Hospital - Long Island
New York, New York, 10016, United States
-
START South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas, 78229, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University Hospital Bern
Bern, 3010, Switzerland
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
University of California Los Angeles
Santa Monica, California, 90404, United States
-
University of Colorado Cancer Center
Aurora, Colorado, 80045, United States
-
University of Florida
Gainesville, Florida, 32610, United States
-
University of Southern California
Los Angeles, California, 90033, United States
-
Universitätsklinikum Heidelberg
Heidelberg, 69120, Germany
-
Virginia Cancer Specialists, PC
Fairfax, Virginia, 22031, United States
-
Virginia Mason Medical Center
Seattle, Washington, 98101, United States
Conditions
Explore the condition pages connected to this study.